Safety and Efficacy of Piromelatine in Mild Alzheimer's Disease Patients (ReCOGNITION)
Status:
Completed
Trial end date:
2019-11-19
Target enrollment:
Participant gender:
Summary
This study is a Phase 2, randomized, placebo controlled, dose ranging study of piromelatine
(5, 20, and 50 mg daily for 6 months) versus placebo to determine an effective dose based on
efficacy (cognitive performance), safety and tolerability in patients with mild dementia due
to AD.